



Used in Lieu of PTO/SB/08A/B  
(Based on PTO 01-08 version)

Substitute for form 1449/PTO			<b>Complete if Known</b>		
			Application Number	10/757,122	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Filing Date	January 13, 2004	
			First Named Inventor	Terrence C. Dahl	
			Art Unit	1617	
			Examiner Name	Y. S. Chong	
			Attorney Docket Number	269.PC	
Sheet	1	of	4		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA*	US-4,808,716	02-28-1989	Holy et al.	
	AB*	US-4,816,570	03-28-1989	Farquhar	
	AC*	US-4,968,788	11-06-1990	Farquhar	
	AD*	US-5,047,407	09-10-1991	Belleau et al.	
	AE*	US-5,151,426	09-29-1992	Belleau et al.	
	AF*	US-5,179,104	01-12-1993	Chu et al.	
	AG*	US-5,204,466	04-20-1993	Liotta et al.	
	AH*	US-5,210,085	05-11-1993	Liotta et al.	
	AI*	US-5,466,806	11-14-1995	Belleau, deceased et al.	
	AJ*	US-5,486,520	01-23-1996	Belleau, deceased et al.	
	AK*	US-5,538,975	07-23-1996	Dionne et al.	
	AL*	US-5,587,480	12-24-1996	Belleau, deceased et al.	
	AM*	US-5,618,820	04-08-1997	Dionne et al.	
	AN*	US-5,627,186	05-06-1997	Cameron et al.	
	AO*	US-5,663,159	09-02-1997	Starrett, Jr. et al.	
	AP*	US-5,696,254	12-09-1997	Mansour et al.	
	AQ*	US-5,733,788	03-31-1998	Bischofberger	
	AR*	US-5,744,596	04-28-1998	Mansour et al.	
	AS*	US-5,756,706	05-26-1998	Mansour et al.	
	AT*	US-5,763,606	06-09-1998	Mansour et al.	
	AU*	US-5,792,756	08-11-1998	Starrett, Jr. et al.	
	AV*	US-5,814,639	09-29-1998	Liotta et al.	
	AW*	US-5,859,021	01-12-1999	Cameron et al.	
	AX*	US-5,905,082	05-18-1999	Roberts et al.	
	AY*	US-5,914,331	06-22-1999	Liotta et al.	
	AZ*	US-5,922,695	07-13-1999	Arimilli et al.	
	AA1*	US-5,935,946	08-10-1999	Munger, Jr. et al.	
	AB1*	US-5,977,089	11-02-1999	Arimilli et al.	
	AC1*	US-6,043,230	03-28-2000	Arimilli et al.	
	AD1*	US-6,057,305	05-02-2000	Holy et al.	
	AE1*	US-6,069,249	05-30-2000	Arimilli et al.	
	AF1*	US-6,113,920	09-05-2000	Maye et al.	
	AG1*	US-6,114,343	09-05-2000	Liotta et al.	
	AH1*	US-6,127,121	10-03-2000	Meyer, Jr. et al.	
	AI1*	US-6,143,877	11-07-2000	Meyer et al.	
	AJ1*	US-6,177,435	01-23-2001	Larder et al.	
	AK1*	US-6,180,639	01-30-2001	Coates et al.	
	AL1*	US-6,215,004	04-10-2001	Painter et al.	
	AM1*	US-6,312,662	11-06-2001	Erion et al.	
	AN1*	US-6,417,191	07-09-2002	Barry et al.	
	AO1*	US-6,475,491	11-05-2002	Johnson et al.	
Examiner Signature				Date Considered	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/757,122	
			Filing Date	January 13, 2004	
			First Named Inventor	Terrence C. Dahl	
			Art Unit	1617	
			Examiner Name	Y. S. Chong	
Sheet	2	of	4	Attorney Docket Number	269.PC

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO-00/25797	05-11-2000	Triangle Pharmaceuticals Inc et al.		
	BB	WO-01/38584	05-31-2001	Epoch Biosciences Inc		
	BC	WO-02/068058	09-06-2002	Triangle Pharmaceuticals Inc et al.		
	BD	WO-02/070518	09-12-2002	Triangle Pharmaceuticals Inc et al.		
	BE	WO-02/08241	01-31-2002	Gilead Sciences Inc et al.		
	BF	WO-04/064846	08-05-2004	Gilead Sciences Inc et al.		
	BG	WO-91/19721	12-26-1991	Glazier Arnold		
	BH	WO-92/14743	09-03-1992	Univ Emory		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/757,122
			Filing Date	January 13, 2004
			First Named Inventor	Terrence C. Dahl
			Art Unit	1617
			Examiner Name	Y. S. Chong
			Attorney Docket Number	269.PC
Sheet	3	of	4	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	"Anti-HIV Drug Updates--Three Drugs on the Near Horizon," <i>Project Inform Perspective</i> (2003) 35:4-7		
	CB	BENZARIA et al. "Synthesis, in Vitro Antiviral Evaluation, and Stability Studies of Bis (S-acyl-2-thioethyl) Ester Derivatives of 9-[2-(Phosphonomethoxy(ethyl)adenine (PMEA) as Potential PMEA Prodrugs with Improved Oral Bioavailability," <i>J. Med. Chem.</i> (1996) 39:4958-4965		
	CC	CHAPMAN et al. "Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340, "Nucleosides, Nucleotides & Nucleic Acids," (2001) 20(4-7):621-628		
	CD	DE CLERQ, Erik, "New Anti-HIV Agents and Targets," <i>Medicinal Research Reviews</i> , (2002) 22(6):531-565		
	CE	De LOMBAERT, et al. "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors" <i>J. Med. Chem.</i> (1994) 37:498-511		
	CF	FARQUHAR et al. "Biologically Reversible Phosphate-Protective Groups," <i>Journal of Pharmaceutical Sciences</i> (1983) 72(3):324-325		
	CG	FELL et al. "The Tensile Strength of Lactose Tablet," <i>J. Pharm. Pharmac.</i> (1968) 657-659		
	CH	HOSTETLER et al. "Greatly Enhance Inhibition of Human Immunodeficiency Virus Type I Replication in CEM and HT4-6C Cells by 3'-Deoxythymidine Diphosphate Dimyristoylglycerol, a Lipid Prodrug of 3'-Deoxythymidine," <i>Antimicrobial Agents and Chemotherapy</i> (1992) 36(9):2025-2029		
	CI	JONES et al. "Minireview: Nucleotide Prodrugs," <i>Antiviral Research</i> (1995) 27:1-17		
	CJ	KHAMNEI et al. "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs," <i>J. Med. Chem.</i> (1996) 39:4109-4115		
	CK	KUCERA et al. "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation," (1990) <i>AIDS Research and Human Retroviruses</i> , 6(4):491-501		
	CL	LEE et al. International Conference on Retroviruses and Opportunistic Infections (2002) 9th Conference, February 24-28, Abs 384-T.		
	CM	MITCHELL et al. "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate," <i>J. Chem. Soc. Perkin Trans.</i> (1992) 2345-2353		
	CN	MULATO, A.S. et al. "Anti-HIV Activity of Adefovir (PMEA) and PMPA in Combination with Antiretroviral Compounds: In Vitro Analyses" <i>Antiviral Research, Elsevier Science B.V., Amsterdam, NL</i> , (1997) 36(2):91-97		
	CO	MURRY, Jeffrey P. et al. "Reversion of the M184V Mutation in Simian Immunodeficiency Virus Reverse Transcriptase is Selected by Tenofovir, even in the Presence of Lamivudine," <i>Journal of Virology</i> (2003) 77(2):1120-1130.		
	CP	PALELLA et al. <i>N. Engl J. Med.</i> (1998) 338-853-860		
	CQ	PIANTADOSI et al. "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity," <i>J. Med. Chem.</i> (1991) 34:1408-1414		
	CR	PUECH et al. "Intracellular Delivery of Nucleoside Monophosphates Through a Reductase-Mediated Activation Process," <i>Antiviral Research</i> (1993) 22:155-174		
	CS	QUAST et al. (1974) <i>Synthesis</i> 490		

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/757,122	
			Filing Date	January 13, 2004	
			First Named Inventor	Terrence C. Dahl	
			Art Unit	1617	
			Examiner Name	Y. S. Chong	
Sheet	4	of	4	Attorney Docket Number	269.PC

CT	RICHMAN, D.D., "Antiretroviral Activity of Emtricitabine, a Potent Nucleoside Reverse Transcriptase Inhibitor," <i>Antiviral Therapy</i> (2001) 6(2):83-88	
CU	RICHMAN, D.D., <i>Nature</i> (2001) 410:995-1001	
CV	RISTIG, Maria B. et al. "Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/Hepatitis B Virus-coinfected Individuals for Whom Interferon-Alpha and Lamivudine Therapy have Failed," <i>Journal of Infectious Diseases</i> (2002) 186(12):1844-1847.	
CW	SIDDIQUI et al. "Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR," <i>J. Med. Chem</i> (1999) 42:4122-4128	
CX	YUAN et al. "Degradation Kinetics of Oxycarbonyloxymethyl Prodrugs of Phosphonates in Solution," <i>Pharmaceutical Research</i> (2001) 18(2):234-237	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.